1. Therapeutic Targeting of Fibroblast Growth Factor Receptors in Gastric Cancer
    Mikito Inokuchi et al, 2015, Gastroenterology Research and Practice CrossRef
  2. Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma
    Anne von Mässenhausen et al, 2016, Targ Oncol CrossRef
  3. Second-line treatment of metastatic gastric cancer: Current options and future directions
    Dheepak Kanagavel, 2015, WJG CrossRef
  4. Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer
    Masakazu Yashiro, 2016, WJG CrossRef
  5. Association between FGFRs and the susceptibility of digestive and reproductive system cancers in Chinese population
    Jia-kang Wang et al, 2017, Mol. Cell. Toxicol. CrossRef
  6. Low-level clonal FGFR2 amplification defines a unique molecular subtype of intrahepatic cholangiocarcinoma in a Chinese population
    Xiao-Hong Pu et al, 2018, Human Pathology CrossRef
  7. Established gastric cancer cell lines transplantable into C57BL/6 mice show fibroblast growth factor receptor 4 promotion of tumor growth
    Masami Yamamoto et al, 2018, Cancer Sci CrossRef
  8. Fibroblast growth factor receptors as treatment targets in clinical oncology
    Masaru Katoh, 2018, Nat Rev Clin Oncol CrossRef
  9. FGFR1 is an independent prognostic factor and can be regulated by miR-497 in gastric cancer progression
    Gang Xie et al, 2018, Braz J Med Biol Res CrossRef
  10. Association of gastric cancer main signaling pathway gene expression with metastasis
    F. M. Kipkeeva et al, 2019, Rossijskij bioterapevtičeskij žurnal CrossRef
  11. FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival
    Soomin Ahn et al, 2016, Mod Pathol CrossRef
  12. Circular RNA hsa_circRNA_103809 promoted hepatocellular carcinoma development by regulating miR‐377‐3p/FGFR1/ERK axis
    Wei Zhan et al, 2019, J Cell Physiol CrossRef
  13. Global transcriptome and sequenome analysis of formalin-fixed salivary epithelial-myoepithelial carcinoma specimens
    Isabel Fonseca et al, 2015, Genes Chromosomes Cancer CrossRef
  14. From Molecular Classification to Targeted Therapeutics: The Changing Face of Systemic Therapy in Metastatic Gastroesophageal Cancer
    Adrian Murphy et al, 2015, Gastroenterology Research and Practice CrossRef
  15. Emerging kinase inhibitors of the treatment of gastric cancer
    Bruno Vincenzi et al, 2015, Expert Opinion on Emerging Drugs CrossRef
  16. Fibroblast growth factor receptor 1 gene amplification in gastric adenocarcinoma.
    Manuel H Schäfer et al, 0 CrossRef
  17. Update on gastric cancer treatments and gene therapies
    Alessio Biagioni et al, 2019, Cancer Metastasis Rev CrossRef
  18. FGFR Family Members Protein Expression as Prognostic Markers in Oral Cavity and Oropharyngeal Squamous Cell Carcinoma
    Koos Koole et al, 2016, Mol Diagn Ther CrossRef
  19. Different clinical significance of FGFR1–4 expression between diffuse-type and intestinal-type gastric cancer
    Mikito Inokuchi et al, 2017, World J Surg Onc CrossRef
  20. A novel non-ATP competitive FGFR1 inhibitor with therapeutic potential on gastric cancer through inhibition of cell proliferation, survival and migration
    Jianzhang Wu et al, 2017, Apoptosis CrossRef
  21. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification
    E. Van Cutsem et al, 2017 CrossRef
  22. Integrated Analysis of Structural Variation and RNA Expression of FGFR2 and Its Splicing Modulator ESRP1 Highlight the ESRP1amp-FGFR2norm-FGFR2-IIIchigh Axis in Diffuse Gastric Cancer
    Sara Pinto Teles et al, 2019, Cancers CrossRef
  23. Prognostic roles for fibroblast growth factor receptor family members in malignant peripheral nerve sheath tumor
    Wenya Zhou et al, 2016, Oncotarget CrossRef
  24. A novel gene expression-based prognostic scoring system to predict survival in gastric cancer.
    Pin Wang et al, 0 CrossRef
  25. Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway
    Feng Wang et al, 2015, Oncotarget CrossRef
  26. FGFR4: A promising therapeutic target for breast cancer and other solid tumors
    Kevin M. Levine et al, 2020, Pharmacology & Therapeutics CrossRef
  27. Expression Atlas of FGF and FGFR Genes in Pancancer Uncovered Predictive Biomarkers for Clinical Trials of Selective FGFR Inhibitors
    Yuan Li et al, 2020, BioMed Research International CrossRef
  28. LncRNA AGAP2-AS1 augments cell viability and mobility, and confers gemcitabine resistance by inhibiting miR-497 in colorectal cancer
    Sen Hong et al, 2020, Aging CrossRef
  29. The changing face of gastric cancer: epidemiologic trends and advances in novel therapies
    Raghav Chandra et al, 2020, Cancer Gene Ther CrossRef
  30. null
    Gulden Olgun et al, 2020 CrossRef
  31. Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours
    Petri Bono et al, 2020, ESMO Open CrossRef
  32. ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
    Tim H. Holmström et al, 2019, Mol Cancer Ther CrossRef
  33. Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer
    Masakazu Yashiro et al, 2021, Sci Rep CrossRef
  34. Combined De-Repression of Chemoresistance Associated Mitogen-Activated Protein Kinase 14 and Activating Transcription Factor 2 by Loss of microRNA-622 in Hepatocellular Carcinoma
    Valerie Fritz et al, 2021, Cancers CrossRef
  35. Atractylenolide III predisposes miR‐195‐5p/FGFR1 signaling axis to exert tumor‐suppressive functions in liver cancer
    Langqing Sheng et al, 2021, J Food Biochem CrossRef
  36. Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK
    David K. Lau et al, 2021, Mol Cancer Ther CrossRef
  37. Discovery of 4,6‐Disubstituted Pyrimidine Derivatives as Novel Dual VEGFR2/FGFR1 Inhibitors
    Jin‐Yang Zhang et al, 2021, Chem. Biodiversity CrossRef
  38. Identification of novel targets of miR-622 in hepatocellular carcinoma reveals common regulation of cooperating genes and outlines the oncogenic role of zinc finger CCHC-type containing 11
    Anne Gaza et al, 2021, Neoplasia CrossRef
  39. miR-301a-3p induced by endoplasmic reticulum stress mediates the occurrence and transmission of trastuzumab resistance in HER2-positive gastric cancer
    Jing Guo et al, 2021, Cell Death Dis CrossRef
  40. Peptibody Based on FGFR1-Binding Peptides From the FGF4 Sequence as a Cancer-Targeting Agent
    Karolina Jendryczko et al, 2021, Front. Pharmacol. CrossRef
  41. FGFR2 overexpression and compromised survival in diffuse-type gastric cancer in a large central European cohort
    Thorben Schrumpf et al, 2022, PLoS ONE CrossRef